AviadoBio
AviadoBio is dedicated to transforming lives through innovative gene therapies targeting neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With a neuroanatomy-led approach and proprietary platforms, the company aims to maximize therapeutic potential by delivering gene therapies directly to the central nervous system, potentially halting or reversing neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Products
AVB-101 (AAV-based gene supplementation therapy)
An investigational AAV-based, single-administration gene supplementation therapy designed to deliver a functional copy of a deficient CNS gene via targeted intrathalamic infusion to restore protein levels in brain tissue.
AVB-101 (AAV-based gene supplementation therapy)
An investigational AAV-based, single-administration gene supplementation therapy designed to deliver a functional copy of a deficient CNS gene via targeted intrathalamic infusion to restore protein levels in brain tissue.
Services
Early-phase clinical trial execution (Phase 1/2)
Design and conduct of early-phase open-label clinical studies for investigational CNS gene therapies, including collaboration with neurology and neurosurgery sites.
Preclinical development and in vivo validation
In vitro assay development and in vivo efficacy/toxicity testing using disease-relevant transgenic animal models and established potency readouts.
CNS delivery procedure development
Development and refinement of neurosurgical procedures and delivery technologies to achieve targeted CNS biodistribution (e.g., intrathalamic infusion, spinal/subpial delivery).
Analytical method development and potency assay services
Development of analytical methods (HPLC) and quantitative potency assays (RT-ddPCR) for characterization, quality control and release testing of AAV vector products.
Early-phase clinical trial execution (Phase 1/2)
Design and conduct of early-phase open-label clinical studies for investigational CNS gene therapies, including collaboration with neurology and neurosurgery sites.
Preclinical development and in vivo validation
In vitro assay development and in vivo efficacy/toxicity testing using disease-relevant transgenic animal models and established potency readouts.
CNS delivery procedure development
Development and refinement of neurosurgical procedures and delivery technologies to achieve targeted CNS biodistribution (e.g., intrathalamic infusion, spinal/subpial delivery).
Analytical method development and potency assay services
Development of analytical methods (HPLC) and quantitative potency assays (RT-ddPCR) for characterization, quality control and release testing of AAV vector products.
Expertise Areas
- CNS gene therapy development
- AAV vector design and engineering
- RNA interference therapeutics (miRNA/RNAi)
- Neuroanatomy-led delivery strategies
Key Technologies
- Adeno-associated virus (AAV) vectors
- AAV9-based constructs
- AAV-delivered RNA interference (miRNA/RNAi)
- Intrathalamic infusion delivery